AN2 Therapeutics, Inc.ANTX
What AN2 Therapeutics, Inc. does.
All brand names or trademarks appearing in this report are the property of their respective owners. Unless the context requires otherwise, references in this report to “ AN2,” “we,” “our,” the “Company” or the “Registrant” refer to AN2 Therapeutics.
We are a clinical stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics derived from our boron chemistry platform. Our development pipeline spans hematologic diseases, infectious diseases, and oncology with three Phase 2 studies expected to initiate in 2026, two preclinical candidates, as well as advanced research programs focused on targets in oncology, bone disorders, and infectious diseases. We are committed to delivering high-impact drugs to patients that address critical unmet needs and improve health outcomes.
In March 2026, we announced our plan to expand the development of oral epetraborole into a Phase 2 proof-of-concept clinical study in adults with phlebotomy-dependent polycythemia vera ( “PV”). PV is a blood cancer characterized by overproduction of red blood cells in the bone marrow. This overproduction increases hematocrit, which can lead to serious medical complications including arterial and venous thromboembolic events. If untreated, PV can be life-threatening. Despite available therapies, many patients experience uncontrolled hematocrit levels and persistent symptom burden, requiring long-term management to maintain adequate disease control. PV is estimated to affect approximately 155,000 people in the U.S.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | — | -$21.5M | -$41.0M | -$64.7M | -$51.3M | -$35.2M |
More on ANTX.
- AN2 Therapeutics, Inc. summary
- AN2 Therapeutics, Inc. financial statements
- AN2 Therapeutics, Inc. key metrics
- AN2 Therapeutics, Inc. health scores and style box
- AN2 Therapeutics, Inc. earnings
- AN2 Therapeutics, Inc. dividends
- AN2 Therapeutics, Inc. valuation
- AN2 Therapeutics, Inc. ownership and insiders
- AN2 Therapeutics, Inc. peers
Figures from AN2 Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.